Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Rating of “Moderate Buy” by Analysts

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has been given a consensus recommendation of “Moderate Buy” by the five ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $20.00.

Several research firms recently commented on ENTA. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Enanta Pharmaceuticals in a report on Thursday, October 10th. JMP Securities reissued a “market outperform” rating and issued a $22.00 price target on shares of Enanta Pharmaceuticals in a report on Wednesday, October 9th. Evercore ISI raised shares of Enanta Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, August 6th. Finally, JPMorgan Chase & Co. lowered their price target on Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating on the stock in a report on Tuesday, August 6th.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC bought a new stake in Enanta Pharmaceuticals in the 2nd quarter worth approximately $35,000. US Bancorp DE lifted its holdings in shares of Enanta Pharmaceuticals by 4,933.7% in the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 4,243 shares during the last quarter. State Board of Administration of Florida Retirement System bought a new position in shares of Enanta Pharmaceuticals during the 1st quarter valued at $118,000. Virtu Financial LLC purchased a new position in Enanta Pharmaceuticals in the 1st quarter worth $191,000. Finally, Quest Partners LLC raised its position in Enanta Pharmaceuticals by 511.2% in the 2nd quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 9,692 shares during the period. Institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Stock Up 1.4 %

Shares of ENTA stock opened at $11.26 on Wednesday. The firm has a market cap of $238.59 million, a P/E ratio of -2.07 and a beta of 0.56. The company has a 50 day moving average of $11.65 and a 200-day moving average of $12.68. Enanta Pharmaceuticals has a 12-month low of $8.08 and a 12-month high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($1.07) earnings per share for the quarter, topping the consensus estimate of ($1.43) by $0.36. The company had revenue of $17.97 million during the quarter, compared to analyst estimates of $17.44 million. Enanta Pharmaceuticals had a negative return on equity of 63.75% and a negative net margin of 160.27%. The firm’s revenue for the quarter was down 4.9% on a year-over-year basis. During the same quarter last year, the firm posted ($1.27) EPS. As a group, equities analysts expect that Enanta Pharmaceuticals will post -5.3 EPS for the current year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.